Answers are grounded in this paper and cite their sources.
Background/Objectives: Machine learning applied to MALDI-TOF mass spectra can flag antimicrobial resistance days before conventional susceptibility testing, but models rarely retain accuracy in a new laboratory. We asked whether this failure can be repaired without target-site labels and, if a few local labels are obtainable, how they should be chosen. Methods: We assembled 72 cross-site species–antibiotic transfer tasks from DRIAMS (eight species, 18 agents, three site pairs) in 12 prespecified clusters. After benchmarking unsupervised adaptation, five label-free shift descriptors were used to choose between Random and Hybrid acquisition at 20, 30 and 50 target labels, under nested leave-one-cluster-out validation with cluster-level sign-flip inference. Results: Source–target separability was uniformly high (domain AUROC: 0.966–1.000), while external PR-AUC varied widely (0.049–0.920), and no unsupervised method restored transportability. The selective policy numerically exceeded Always-Random at all budgets (+0.0084, +0.0078 and +0.0048 PR-AUC; p = 0.064, 0.012 and 0.045). The 30-label result was robust to excluding development tasks, duplicated phenotypes and post hoc descriptor choice, but not to accounting for isolates shared between clusters (p = 0.06–0.09), and the policy did not outperform Always-Hybrid. Conclusions: Site identity persists in MALDI-TOF spectra despite harmonization, so cross-site deployment is better planned around a small local labeling budget than around label-free correction. Shift-informed acquisition is a methodological proof of concept: its gains were small and statistically fragile, it did not outperform Always-Hybrid, and independent laboratory validation and local recalibration are required before any clinical application.
No takes yet. Share an insight, caveat, or question.
Kutlu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: